You are viewing an incomplete version of our website. Please click to reload the website as full version.

anti-Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antibodies

CDKN2A generates several transcript variants which differ in their first exons.

list all antibodies Gene Name GeneID UniProt
Anti-Rat CDKN2A CDKN2A 25163 Q9R0Z3
Anti-Human CDKN2A CDKN2A 1029 P42771 , Q8N726
Anti-Mouse CDKN2A CDKN2A 12578 P51480 , Q64364
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

More Antibodies against Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Interaction Partners

Human Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) interaction partners

  1. Data suggest that gamma-tocotrienol delays cellular senescence of cultured diploid fibroblasts by regulating the cell cycle through down-regulation of expression of p16-INK4a (CDKN2A/cyclin dependent kinase inhibitor 2A) mRNA, of expression/phosphorylation of retinoblastoma protein (RB1), and of expression of cyclin D1 (CCND1 (show CCND1 Antibodies)).

  2. FOXA1 (show FOXA1 Antibodies) promotes cell senescence in EC by interaction with p16INK4a.

  3. we verified that miR (show MLXIP Antibodies)-892b regulates the p19ARF/cyclin D1 (show CCND1 Antibodies)/CDK6 (show CDK6 Antibodies) and Sp-1 (show PSG1 Antibodies)/MMP-9 (show MMP9 Antibodies) signaling networks in bladder cancer cells and may provide a treatment option for advanced-stage bladder cancers.

  4. FISH analysis of the p16/CDKN2A status and BAP1 (show RNF2 Antibodies) immunohistochemistry in the spindled mesothelium provide a more objective means to differentiate between biphasic mesothelioma and epithelioid mesothelioma with atypical stromal cells

  5. p16 overexpression was found in 24.4% of both oropharyngeal squamous cell carcinoma (OSCC) and oral verrucous carcinoma (VC); high-risk human papillomaviruses (HR-HPV), regardless of type, was detected in 15.8% in cases of OSCC and VC combined; findings suggest p16 can be used as a surrogate marker for HR-HPV in OSCC and VC

  6. based on the accuracy of newer diagnostic modalities the surveillance of a radiologically negative neck after primary chemoradiation (CRT (show SLC6A8 Antibodies)) is oncologically safe irrespective of p16 expression of the tumor.

  7. Data show that significant associations between cyclin-dependent kinase (show CDK1 Antibodies) inhibitor p16 upregulation and tumor phenotype or patient prognosis were strictly limited to the subset of transcriptional regulator ERG (show ERG Antibodies) negative cancers.

  8. Increased the expression of tumor suppressor genes such as Cdkn2A, Rb1 (show RB1 Antibodies) and p53 (show TP53 Antibodies).

  9. p16 expression was predominantly diffuse, which was observed in 91.7% of lesions, whereas 8.3% were focal . HPV 52, HPV 16 and 31 were the most prevalent HPV types in high-grade CIN (show PDXP Antibodies) in these indigenous women.

  10. The addition of p16/Ki-67 (show MKI67 Antibodies) to HPV DNA testing leads to a more accurate stratification of CIN (show PDXP Antibodies) in women presenting with minor cytological abnormalities.

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) interaction partners

  1. AMPKalpha2 (show PRKAA2 Antibodies) isoform plays a fundamental role in anti-oxidant stress and anti-senescence

  2. that MEK (show MDK Antibodies) activity induced cell cycle arrest through accumulation of p16/19(cdkn2a)

  3. Data indicate the cyclin-dependent kinase inhibitor 2A (p19Arf) and interferon beta (IFN-beta (show IFNB1 Antibodies)) combination as a cancer immunotherapy strategy.

  4. Our findings reveal a novel role for p16(Ink4a) and cellular senescence in promoting insulin (show INS Antibodies) secretion by beta cells and in regulating normal functional tissue maturation with age.

  5. Loss of Nf2 (show NF2 Antibodies) and Cdkn2a/b have synergistic effects with PDGF-B (show PDGFB Antibodies) overexpression promoting meningioma malignant transformation.

  6. Inactivation of INK4a and ARF induces myocardial proliferation and improves cardiac repair following ischemiareperfusion

  7. loss of p19ARF overcomes senescence of LSECs, allowing immortalization of cells without losing endothelial characteristics.

  8. Increased gene dosage of Ink4a, Arf1 (show ARF1 Antibodies) and p53 (show TP53 Antibodies) delays age-associated central nervous system functional decline.

  9. Dysregulation of the Bmi-1 (show BMI1 Antibodies)/p16Ink4a pathway provokes an aging-associated decline of submandibular gland function.

  10. Results show that epigenetic silencing of p16(Ink4a) in selected liver cells bypassing senescence is a general principle for development of liver tumors with beta-catenin (show CTNNB1 Antibodies) involvement in mice independent of the initial stimulus.

Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antigen Profile

Protein Summary

This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene\; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.

Gene names and symbols associated with CDKN2A

  • cyclin-dependent kinase inhibitor 2A (Cdkn2a) antibody
  • cyclin-dependent kinase inhibitor 2A (LOC100340625) antibody
  • cyclin-dependent kinase inhibitor 2A (CDKN2A) antibody
  • ARF antibody
  • ARF-INK4a antibody
  • CDK4I antibody
  • CDKN2 antibody
  • CMM2 antibody
  • INK4 antibody
  • INK4A antibody
  • INK4a-ARF antibody
  • Ink4a/Arf antibody
  • MLM antibody
  • MTS-1 antibody
  • MTS1 antibody
  • P14 antibody
  • P14ARF antibody
  • P16 antibody
  • p16(INK4a) antibody
  • P16-INK4A antibody
  • p16Cdkn2a antibody
  • P16INK4 antibody
  • p16INK4a antibody
  • P19 antibody
  • p19 antibody
  • P19ARF antibody
  • Pctr1 antibody
  • TP16 antibody

Protein level used designations for CDKN2A

CDK4I , Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4) , cell cycle inhibitor , cell cycle regulator , cyclin-dependent kinase 4 inhibitor A , cyclin-dependent kinase inhibitor 2a p16Ink4a , cyclin-dependent kinase inhibitor 2a p19Arf , p16-INK4 , p16-INK4a , CDK4 inhibitor p16-INK4 , cell cycle negative regulator beta , cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) , multiple tumor suppressor 1 , cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4) , cyclin-dependent kinase inhibitor 2A, isoforms 1/2 , cyclin-dependent kinase inhibitor protein , mitochondrial smARF

GENE ID SPECIES
25163 Rattus norvegicus
100731972 Cavia porcellus
100340625 Oryctolagus cuniculus
1029 Homo sapiens
12578 Mus musculus
Did you look for something else?